News

Nintedanib is the first targeted treatment for IPF to consistently meet the primary endpoint in two international Phase III trials with identical design. In the two 52 week

The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin – a growing epidemic in the US.

The Breakthrough Therapy designation was granted based on interim efficacy and safety results from an ongoing Phase I/II study of CO-1686. CO-1686 is the company’s novel, oral, targeted

In addition, Endo will assume an existing third party royalty obligation on net sales. The transaction will be financed with Endo’s current cash on hand. Sumavel DosePro is

Fabrus has been successful in generating antibodies against very difficult, therapeutically important cell surface receptors and ion channels resulting in an internal pipeline that includes next generation antibodies

This is the fourth proposal Pfizer has made and it believes that the final proposal provides a clear basis for AstraZeneca to extend the period for making a

Pirfenidone, an orally active, anti-fibrotic agent, is an investigational therapy in the US and has not been approved by the US Food and Drug Administration (FDA). It inhibits

The submission is expected to take place in the third quarter of 2014 based on discussions with the FDA regarding the final results of PALOMA-1, a randomized, Phase

The open-label trial involved 12 CIS patients recruited from sites in the US to examine the efficacy of Vesimune over six doses. The trial population included both BCG